Table 1 Baseline characteristics of included RCTs
From: Outcome reporting bias in randomized-controlled trials investigating antipsychotic drugs
Variables | No. of trials (N=48) | % |
|---|---|---|
Results posted on ClinicalTrials.gov | ||
 Yes | 27 | 56 |
 No | 21 | 44 |
Phase of Study (as designated) | ||
 II | 1 | 2.8 |
 II/III | 1 | 2.8 |
 III | 30 | 63 |
 IV | 16 | 33 |
Antipsychotic | ||
 Paliperidone | 11 | 23 |
 Aripiprazole | 8 | 17 |
 Quetiapine | 7 | 15 |
 Lurisadone | 6 | 13 |
 Risperidone | 5 | 10 |
 Olanzapine | 3 | 6.3 |
 Brexpiprazole | 2 | 4.2 |
 Sertindole | 1 | 2.1 |
 Asenapine | 1 | 2.1 |
 Ziprasidone | 1 | 2.1 |
 Cariprazine | 1 | 2.1 |
 Clozapine | 1 | 2.1 |
 Sertindole/quetiapine | 1 | 2.1 |
Funding Source | ||
 Industry | 39 | 81 |
 Other | 9 | 19 |
Mono/multicenter | ||
 Multicenter | 35 | 73 |
 Monocenter | 7 | 15 |
 Not specified | 6 | 13 |
